Amarin Corp Plc (AMRN)

[jessellivermore]

Gen L can not be substituted for the R-I indication because they do not the same indications and usage on the FDA label..There will be no alternative to Vascepa for the CVD event label..No competition..

Since Du did say if the generics market or sell gen V for the R-I indication they would be inducing infringement of Amarin's patents..

From a practical and legal standpoint standpoint Generics (H&R) would be breaking the law if they encourage off label prescriptions using the Marine label..I would say it's going to come down to the label and what the generics put on their label..It's going to be tricky...Its Scylla and Cerberus all over again..Teva will have them trumped for the Marine and Amarin for the R-I label..

I could see both R&H settling....

":>) JL